Tofacitinib Extended Release Tablets 11 Mg

Tofasky‑ER 11 (Tofacitinib Extended Release Tablets 11mg) is an oral Janus kinase (JAK) inhibitor formulated in an extended‑release (ER) version for once‑daily dosing convenience in autoimmune and inflammatory disorders.

🔹 Key Medical Uses

• Rheumatoid Arthritis (RA)

  • For moderate to severe RA in adults with inadequate response/intolerance to methotrexate.

• Psoriatic Arthritis (PsA)

  • Reduces joint pain, swelling, and progression of structural damage.

• Ulcerative Colitis (UC)

  • Indicated for moderate to severe UC when conventional therapy is insufficient.

• Other autoimmune conditions (specialist‑guided use)

  • Sometimes explored in ankylosing spondylitis and other immune‑mediated diseases.

⚙️ How It Works

• Tofacitinib selectively inhibits Janus kinase (JAK) enzymes, blocking cytokine signaling pathways.

• This reduces immune system overactivity → less inflammation, reduced joint damage, and symptom relief.

• Extended release (11mg) allows once‑daily dosing, improving patient compliance compared to immediate‑release 5mg twice daily.